Physician profile
John Saito
NPI 1851352678
$7,775.08
in general payments reported to CMS, 2019-2025
27 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 92% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $719 · 2021: $704 · 2022: $1,395 · 2023: $1,292 · 2024: $822 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,767 · Education: $94.66 · Travel and Lodging: $6.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,767.36 |
| Education | $94.66 |
| Travel and Lodging | $6.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,957.96 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,772.76 | 2021-2024 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $1,131.22 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Jazz Pharmaceuticals INC. | $790.00 | 2019-2023 | Xywav |
| Lilly USA, LLC | $368.28 | 2019-2025 | Zepbound |
| Avadel Cns Pharmaceuticals, LLC | $201.17 | 2023-2025 | Lumryz |
| Merz North America, INC. | $200.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.34 | 2019-2023 | Spiriva Respimat |
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Amgen INC. | $130.07 | 2021-2024 | Tezspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.23 | 2021-2022 | |
| Viatris Specialty LLC | $109.68 | 2025 | Yupelri |
| Genzyme Corporation | $93.27 | 2020-2023 | |
| Allergan, INC. | $76.78 | 2019-2020 | |
| Philips North America LLC | $72.68 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $72.33 | 2021-2025 | Smartvest |
| Mylan Specialty L.P. | $64.57 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $60.62 | 2023 | Sunosi |
| Harmony Biosciences LLC | $56.38 | 2023 | Wakix |
| Inspire Medical Systems, INC. | $41.18 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $27.40 | 2023 | |
| Pulmonx Corporation | $24.32 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Genentech USA, INC. | $22.82 | 2023 | Xolair |
| Grifols USA, LLC | $22.13 | 2021 | |
| Optinose US, INC. | $22.09 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $16.55 | 2021 | |
| Resmed Corp | $13.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Saito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.